The medication is commonly used to help with therapeutic support by addressing several categories of fungal infections and may assist with easing symptoms that interfere with daily functioning. It is considered relevant for managing systemic infections like candidemia and cryptococcal meningitis, as well as mucosal candidiasis, including oral thrush and recurrent vaginal infections.

Quick Fact: Relief for Inflammatory Discomfort

Symptom Category	Therapeutic Benefit
Systemic Symptoms	May assist with easing fever, chills, and profound malaise.
Localized Symptoms	Provides support that helps ease burning, itching, and painful swallowing.
Clinical Context	May assist with maintaining functional stability during acute or recurrent episodes.

---

In clinical scenarios, the medication is commonly used to help alleviate the associated constitutional symptoms—such as fever, chills, and malaise—that arise during deep-seated mycoses. It supports patients during difficult episodes by easing distress. For localized issues, the medication may assist with easing symptoms related to inflammatory or irritative states, such as intense burning and irritation, which helps improve day-to-day comfort during symptomatic periods. The medication is applied across domains where additional symptomatic support is needed.

Regulatory References

1. NIH DailyMed drug label

Who can and cannot use Флуконазол-Тева?

Eligibility for Флуконазол-Тева (Fluconazole) is determined by official regulatory bodies based on age, health conditions, and concomitant medications. The medicine is generally allowed for adults and children older than 6 months for approved indications, with specific guidance available for use in infants.

Classification	Population Restriction
Absolute Contraindication	Patients with known hypersensitivity to Fluconazole or other azole antifungals. Co-administration with specific medications that prolong the QT interval and are metabolized by the CYP3A4 enzyme (e.g., erythromycin, pimozide) is strictly prohibited.
Conditional Use	Patients with impaired kidney function require a dose reduction for multiple-dose therapy. Caution and monitoring are required for patients with liver dysfunction or pre-existing heart rhythm disorders (e.g., QT prolongation).

Use in pregnancy is generally restricted and avoided, especially high-dose or chronic therapy in the first trimester, due to potential risks; it is only considered for severe, life-threatening maternal infections. While use during breastfeeding is deemed acceptable due to low transfer into milk, caution is advised by the manufacturer.

Interactions with other medicines and products

Fluconazole is a moderate inhibitor of cytochrome P450 isoenzyme CYP3A4 and a potent inhibitor of CYP2C9 and CYP2C19. This inhibitory activity is the primary basis for numerous clinically significant drug interactions, leading to increased plasma concentrations of co-administered medicines that are metabolized by these enzymes.

Contraindicated Combinations

Co-administration is strictly contraindicated with medicinal products known to prolong the QT interval and which are metabolized via CYP3A4. This includes agents such as Cisapride, Astemizole, Pimozide, Quinidine, Erythromycin, and Tizanidine. The concomitant use of Terfenadine at fluconazole doses 400 mg per day is also contraindicated due to the risk of serious cardiotoxicity.

Use with Caution and Monitoring

• Anticoagulants (Warfarin): Increased prothrombin time; requires close monitoring and dose adjustment of the anticoagulant.
• HMG-CoA Reductase Inhibitors (Statins): Increased risk of myopathy and rhabdomyolysis for statins metabolized by CYP3A4 or CYP2C9 (e.g., Atorvastatin, Simvastatin).
• Immunosuppressants (Cyclosporine, Tacrolimus): Increased plasma concentrations; requires monitoring of trough levels and dose reduction.
• Oral Hypoglycemics (Sulfonylureas): Increased plasma concentrations, potentially leading to hypoglycemia.
• Phenytoin and Theophylline: Increased plasma levels due to reduced clearance, requiring concentration monitoring.

Interaction with Rifampicin results in a significant decrease in fluconazole exposure (AUC and half-life). Additionally, Hydrochlorothiazide is documented to increase fluconazole plasma levels. Appropriate monitoring or dose adjustments are necessary when fluconazole is used alongside these medicinal products.

Targeted Inhibition of Fungal Sterol Synthesis

This domain outlines the action of Fluconazole as a selective inhibitor of the fungal enzyme Lanosterol 14-alpha-demethylase (CYP51). By blocking this critical de-methylation step, the enzyme inhibition impedes the pathogen's capacity to synthesize ergosterol, the fundamental building block of its cell membrane structure.

---

Cellular Disruption and Loss of Fungal Integrity

The core physiological consequence of the enzyme blockade is the resulting deficiency of ergosterol and the simultaneous accumulation of toxic intermediate sterols. This dual effect severely destabilizes the fungal cell membrane, compromising its structural integrity and function, which results in the inhibition of growth (fungistatic effect) and, under certain conditions, induces pathogen-specific cytotoxicity (fungicidal effect against sensitive strains).

---

️ Mechanistic Constraints and Fungal Counter-Action

This area describes pathogen counter-mechanisms that constrain the drug's action. Fungi can develop resistance by either overproducing the CYP51 target enzyme or by increasing the activity of efflux pumps, which are specialized transport proteins that actively remove the Fluconazole molecule from inside the cell, thereby reducing the intracellular concentration at the CYP51 target site.

Флуконазол-Тева (Fluconazole) is administered through two officially approved routes: Oral (as tablets or suspension) and Intravenous (IV) infusion. The dose of the medicine is maintained as equivalent whether administered orally or intravenously.

Usage patterns are highly dependent on the condition being addressed but typically follow a once-daily (q24h) frequency due to the drug's extended half-life. For many infections, therapy is initiated with a loading dose—often double the daily amount—on Day 1 to achieve effective drug concentrations rapidly, followed by a lower maintenance dose. Treatment duration varies widely, ranging from a single dose regimen for certain acute infections to long-term maintenance for relapse prevention in chronic conditions.

The medicine may be taken with or without food, as food intake does not significantly affect absorption. When using the IV form, the solution must be administered via infusion at a regulated rate, which typically should not exceed 10 to 20 milliliters per minute. The oral suspension requires careful reconstitution with a measured volume of water before use and must be shaken well for proper mixing.

Dose modification is a mandatory consideration for certain patient populations. For adults with renal impairment, defined by low creatinine clearance, the dose must be substantially reduced to approximately 50% of the recommended amount after the initial loading dose. Furthermore, patients undergoing hemodialysis must receive their full recommended dose immediately following the dialysis procedure. The application of these explicit, label-based rules defines the official procedural structure for using the medicine.

Evidence for Invasive and Systemic Candidiasis

Research has extensively examined the agent in conditions characterized by systemic or functional imbalance, such as when Candida infection spreads to the bloodstream (candidemia). Studies include Randomized Controlled Trials (RCTs) and Systematic Reviews that explored outcomes related to overall survival and microbiological response (changes in culture results). Research identifies intrinsic resistance in some species (e.g., C. krusei) and notes that other common strains may display reduced susceptibility. Long-term effects are not fully established beyond initial follow-up.

---

Evidence for Mucosal and Genital Candidiasis

The evidence base for localized fungal infections, like oral thrush or recurrent vaginal yeast infections, includes numerous Randomized, Controlled Trials. Studies monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Findings describe patterns related to changes in acute symptoms over the observed interval. What is not fully established is the specific set of factors driving the development of treatment-refractory disease in individuals with advanced underlying conditions.

---

Evidence for Cryptococcal Meningitis

Research was studied for this serious fungal infection of the central nervous system, focusing on both the acute treatment phase and long-term suppressive therapy studies that examine recurrence. Trials explored outcomes such as overall mortality and time to achieve culture-negative status in the cerebrospinal fluid (CSF). Studies reported that microbiological clearance rates were slower when the drug was observed as a single agent for initial treatment, compared to multi-drug regimens.

---

Evidence in Special Populations and Gaps

Research was evaluated in specific groups, including Adults with HIV/AIDS, Children (e.g., neonates), and patients with neutropenia. While these studies provide context, data for certain groups remain insufficient. Finally, evidence quality varies across studies, meaning different levels of certainty exist across the various indications, and long-term effects are not fully established regarding functional outcomes following complex treatment.

Key Studies & References

1. Cryptococcosis: Adult and Adolescent OIs | NIH - Clinical Info .HIV.gov (Guideline for Cryptococcal Meningitis)
2. Fluconazole resistance in Candida species: a current perspective (Mechanism of resistance in C. krusei and C. glabrata)

Common questions about Флуконазол-Тева (FAQ)

Q: What kind of fungal infections does Флуконазол-Тева treat?

A: According to official regulatory documents, Флуконазол-Тева is approved to treat various fungal infections. This includes infections caused by Candida species, such as candidiasis of the mouth, throat, or vagina, as well as systemic infections like candidemia. The medication is also officially indicated for treating cryptococcal meningitis.

Q: How quickly does Флуконазол-Тева usually start to work?

A: Official prescribing information indicates that the drug is rapidly and almost completely absorbed after being taken orally. Peak concentrations in the blood are typically reached within one to two hours. However, regulatory information does not specify the time frame in which an individual can expect to notice symptomatic improvement.

Q: Does Флуконазол-Тева work for all types of thrush?

A: Official documents state that the agent is effective against Candida species, which are the primary cause of thrush, including mucosal and genital infections. However, the regulatory labeling notes that certain fungal species, such as Candida krusei, are known to be intrinsically resistant to the medication. This means that not all types of fungi causing infection may be susceptible to treatment.

Q: Are there any food or drinks that should be avoided when taking this medicine?

A: Regulatory documents state that this medication can generally be taken either with or without food, as food intake does not significantly impact its absorption. The official product information does not list specific foods or common drinks that need to be avoided. Information regarding the use of alcohol is typically not addressed in the product labeling.

Q: What are the signs of a severe allergic reaction to fluconazole?

A: The safety profile for fluconazole notes rare but serious adverse events, including the classified reactions of anaphylaxis and Stevens-Johnson syndrome. These types of severe reactions are officially documented to include symptoms such as severe blistering, significant difficulty breathing, or swelling in the face, lips, or throat area.

Q: Can this medication cause skin rashes?

A: According to the official product information, a general skin rash is documented as an uncommon side effect, meaning it may be observed in approximately 1 in 100 to 1 in 1,000 users. In addition to this observation, the safety profile also documents rare but severe cutaneous reactions, which are categorized separately.

Q: How does Флуконазол-Тева interact with medications for anxiety or depression?

A: Official regulatory documents describe fluconazole as an inhibitor of certain liver enzymes, specifically CYP3A4, CYP2C9, and CYP2C19. This means that co-administered medicines that are metabolized by these enzymes may have increased concentrations in the body. Since several classes of medications used for anxiety and depression rely on these same enzymes, this potential for increased concentration must be considered.

Q: What is the shelf life or expiry information for Флуконазол-Тева?

A: Regulatory documents provide specific stability constraints for the different dosage forms. For instance, the stability period for the reconstituted suspension is officially documented as 14 days when stored within the recommended temperature range and must not be frozen. Storage conditions for the oral tablets and dry powder are also specified on the official label, primarily requiring that they be kept in the original container.

How to Store and Dispose of Флуконазол-Тева (Fluconazole-Teva)

The official storage conditions for this medication vary by form, and disposal must follow regulatory guidelines.

Storage Requirements

Dosage Form	Temperature Requirement	Stability Constraint
Oral Tablets/Dry Powder	Store below 30 C (mathbf86 F) (Controlled Room Temp)	Keep in tightly closed original container
Reconstituted Suspension	Store between 2 C and 30 C	Do not freeze; discard after 14 days

All forms must be protected from excessive heat, moisture, and light. The medicine must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal

Expired or unused Флуконазол-Тева must be disposed of according to local and national regulations. The product should not be disposed of via wastewater. Disposal should primarily be handled through a local pharmacy or designated drug take-back program.